We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Dilon Acquires Navigator Gamma Probe Company

By HospiMedica International staff writers
Posted on 13 Jan 2014
Dilon Technologies, Inc. More...
(Newport News, VA, USA) has acquired the assets of the Navigator gamma probe business from RMD Instruments Corp. (Watertown, MA, USA), a subsidiary of Dynasil Corporation of America.

RMD Instruments manufactures and sells a range of intraoperative surgical probes that are distributed both in the United States and worldwide. The acquired products are used in surgery for procedures such as pulmonary wedge resection and sentinel lymph node biopsy. The company recently introduced its Navigator 2.0 wireless probe, which has been very well received by the market place.

“In addition to our market leadership in the small field-of-view molecular breast imaging market, this acquisition is consistent with our objective of expanding our product offering in both the diagnostic and surgical segments of the market and comes on the heels of our recent agreement with Digirad [Suwanee, GA, USA],” commented Robert G. Moussa, Dilon’s CEO.

“We are pleased to have found a wonderful home for our Navigator Probe technology, one of the most widely used gamma probes for cancer surgery in the marketplace. Dilon Technologies is well situated to expand the gamma probe market and we look forward to working with them over the coming months to transition the product from our manufacturing facility to Dilon,” commented Peter Sulick, Dynasil’s chairman and interim CEO.

Dynasil, for the time being, will continue to manufacture and distribute the products, maintaining continuity in supply and regulatory compliance.

Dilon Technologies’ keystone product, the Dilon molecular imaging system (MBI), is a high-resolution, small field-of-view digital gamma camera, optimized for MBI/breast-specific gamma imaging (BSGI). MBI utilizes radiotracer uptake to detect the increased metabolic activity of breast lesions and therefore, is not affected by breast density. Both the Dilon 6800 and Acella systems provide high photon sensitivity; and Dilon’s GammaLoc system is the only localization device on the market to enable molecular-guided breast biopsy.

Digirad is one of the largest US providers of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers, and also sells medical diagnostic imaging systems for nuclear cardiology and general nuclear medicine applications.

Related Links:

Dilon Technologies
RMD Instruments
Digirad



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Mammography System (Analog)
MAM VENUS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The new 3D heart mapping system visualizes all four chambers in real time (Photo courtesy of UPV)

Whole-Heart Mapping Technology Provides Comprehensive Real-Time View of Arrhythmias

Cardiac arrhythmias can be difficult to diagnose and treat because current mapping systems analyze the heart one chamber at a time. This fragmented view forces clinicians to infer electrical activity they... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.